Issues related to the FDA and Health and Human Services pertaining to CBD policies; Issues related to the regulation of intoxifying hemp; Issues related to cannabis research; Appropriations issues related to House Ag/FDA Appropriations bill pertaining to FDA enforcement of non-FDA approved, cannabis derived CBD products.
2025 · 2nd Quarter (Apr 1 - June 30)
TIBER CREEK GROUP ON BEHALF OF JAZZ PHARMACEUTICALS
Filed by B HALL STRATEGIES, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- Registration
- Posted
- Jul 15, 2025
- Income
- Not reported
- Expenses
- Not reported
- Registrant
- B HALL STRATEGIES, LLC
- Filing UUID
- 25ea1120-03b3-4117-afaa-c8fb38935f94
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to the FDA and Health and Human Services pertaining to CBD policies; Issues related to the regulation of intoxifying hemp; Issues related to cannabis research; Appropriations issues related to House Ag/FDA Appropriations bill pertaining to FDA enforcement of non-FDA approved, cannabis derived CBD products.
Issues related to the FDA and Health and Human Services pertaining to CBD policies; Issues related to the regulation of intoxifying hemp; Issues related to cannabis research; Appropriations issues related to House Ag/FDA Appropriations bill pertaining to FDA enforcement of non-FDA approved, cannabis derived CBD products.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.